Engineered immune cells take on Hard-to-Treat prostate cancer

NCT ID NCT07156045

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new cell therapy called anti-PSMA CAR NK cells in 10 people with metastatic castration-resistant prostate cancer (mCRPC), a form of prostate cancer that no longer responds to hormone therapy. The treatment uses immune cells engineered to target a protein called PSMA on cancer cells. The main goal is to check safety and side effects, with early signs of effectiveness also being measured.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: anti-PSMA CAR NK cells
What this could lead to: If it works, this could point toward a new cell therapy for advanced prostate cancer that has stopped responding to standard hormone treatment.
What could go wrong: This is a very early, small trial (10 people) focused on safety. The treatment may not shrink tumors or extend life, and there are risks of serious side effects from the cell infusion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

castration-resistant prostate carcinoma metastatic prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER CASTRATION-RESISTANT PROSTATE CANCER

Contacts and locations

Show contact details

Locations

Cancer Hospital Chinese Academy of Medical Sciences
RECRUITING

Beijing, Beijing Municipality, 100000, China

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.